ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell (Nasdaq: ICCC) will report unaudited results for the quarter ended March 31, 2026 after market close on May 14, 2026 and plans a conference call on May 15, 2026 at 9:00 AM ET.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) will report unaudited results for the quarter ended March 31, 2026 after market close on May 14, 2026 and plans a conference call on May 15, 2026 at 9:00 AM ET.

ImmuCell expects no change to preliminary sales disclosed April 8, 2026, and intends to file its Form 10-Q on May 14, 2026 after market close.

Argus May 8 session

-4.96% close to close Open Argus

Details

News Market Reaction – ICCC

On May 8, the first trading day after this news, ICCC closed 4.96% below the previous close.

Data tracked by StockTitan Argus for the May 8 session.

Key Figures

Earnings call time: 9:00 AM ET Earnings call date: May 15, 2026 Results release date: May 14, 2026 +5 more

Earnings call time: 9:00 AM ET; Conference call on May 15, 2026
Earnings call date: May 15, 2026; Q1 2026 results conference call
Results release date: May 14, 2026; Unaudited Q1 2026 financial results after market close
Quarter end date: March 31, 2026; Quarter for which results will be reported
Replay end date: May 22, 2026; Teleconference replay availability
Replay access code: #9452004; Required code to access call replay
U.S. dial-in: (844) 855-9502; Toll-free conference call access
International dial-in: (412) 317-5499; International conference call access

Previous Earnings date Reports

2 past events · Latest: Feb 18

Same Type 2 events

Feb 18
Earnings date notice

24h Move

+3.9%

Set March 4, 2026 earnings release and March 5 conference call with no sales changes.
Nov 06
Earnings date notice

24h Move

-3.3%

Announced November 13, 2025 Q3 results timing and call, affirming prior prelim sales.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 10-q, unaudited financial results, colostrum-derived, antibodies, +1 more

5 terms

form 10-q regulatory

"The Company expects to file its Quarterly Report on Form 10-Q on May 14, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

unaudited financial results financial

"expects to report unaudited financial results for the quarter ended March 31, 2026"

Unaudited financial results are company-reported numbers for revenue, profit and cash flow that have not been independently checked by external accountants; think of them as a self-prepared summary rather than a third-party-verified report. They matter to investors because they provide timely insight into a company's recent performance, but carry more uncertainty—like a draft you rely on for quick decisions until a certified review confirms the details.

colostrum-derived medical

"provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies"

Colostrum-derived describes products or ingredients obtained from colostrum, the nutrient- and antibody-rich first milk produced by mammals after birth. For investors, the label signals sourcing and regulatory considerations: these ingredients can command premium prices because of perceived health benefits, but they also bring questions about consistency, safety testing, manufacturing controls and supply limits that can affect product claims, approvals and profit margins.

antibodies medical

"orally delivered antibodies against the principal viral and bacterial causes of scours"

Antibodies are proteins made by the body’s immune system that recognize and bind to specific foreign substances, like virus or bacteria pieces, much like a lock matched to a key. For investors, antibodies matter because they are the basis for diagnostic tests, vaccines and many therapies — changes in antibody data or the success of antibody-based products can directly affect a healthcare company’s revenue prospects and perceived value.

neonatal calf diarrhea medical

"Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases"

Neonatal calf diarrhea is an illness that affects newborn calves, causing frequent watery stools that can quickly lead to dehydration, poor growth, and sometimes death if not treated. For investors, it matters because outbreaks reduce herd productivity, increase veterinary and replacement costs, and can disrupt milk and meat supply — similar to how a flu season can raise costs and lower output for a human workforce.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/07/2026 - 04:05 PM

Conference Call Scheduled for Friday, May 15, 2026 at 9:00 AM ET

PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026.

The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 22, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #9452004.

The Company anticipates no change to the preliminary sales results for the quarter ended March 31, 2026 that were disclosed on April 8, 2026. The Company expects to file its Quarterly Report on Form 10-Q on May 14, 2026 after the market closes.

About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense^®line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.

Contacts:		Olivier te Boekhorst, President and CEO
		Timothy C. Fiori, Chief Financial Officer
		ImmuCell Corporation
		investor.relations@immucell.com

		Joe Diaz, Robert Blum and Joe Dorame
		Lytham Partners, LLC
		iccc@lythampartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ImmuCell (ICCC) release its unaudited Q1 2026 financial results?

ImmuCell will release unaudited results for the quarter ended March 31, 2026 after market close on May 14, 2026. According to ImmuCell, the company expects to file its Form 10-Q on May 14, 2026 after the market closes.

How can investors join the ImmuCell (ICCC) conference call on May 15, 2026?

Investors can join the May 15, 2026 conference call at 9:00 AM ET by dialing (844) 855-9502 or (412) 317-5499 for international. According to ImmuCell, a teleconference replay will be available through May 22, 2026 with access code #9452004.

Will ImmuCell (ICCC) change its preliminary sales figures for Q1 2026?

ImmuCell anticipates no change to the preliminary sales results for the quarter ended March 31, 2026. According to ImmuCell, the company reaffirmed the April 8, 2026 preliminary sales disclosure without expected revisions.

Where can I find ImmuCell (ICCC) investor materials and press releases after the Q1 2026 report?

ImmuCell posts investor materials and press releases on its investor website at immucell.com/investors. According to ImmuCell, additional details, including the Form 10-Q filing, will be available following the May 14, 2026 after-market filing.

How long will the ImmuCell (ICCC) teleconference replay be available after the May 15, 2026 call?

The teleconference replay will be available until May 22, 2026 via toll-free replay numbers. According to ImmuCell, listeners should use replay access code #9452004 to access the recorded call during that window.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026